Navigation Links
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Date:11/12/2007

in the placebo group (p-value less than 0.0001) sleep problems Index I was -9.5 in the ORENCIA group and -1.4 in the placebo group (p-value less than 0.0001) and Index II was -9.8 in the ORENCIA group and -2.1 in the placebo group (p-value less than 0.0001). MOS-sleep scales measuring awakened short of breath or with headache and snoring were not significantly different in the ATTAIN group. In the AIM study, measurement of sleep disturbance in the ORENCIA group was -13.0 and -8.9 in the placebo group (p-value equals 0.0197), sleep problems Index I was -9.4 in the ORENCIA group and -6.7 in the placebo group (p-value equals 0.0476) and Index II was -10.4 in the ORENCIA group and -7.3 in the placebo group (p-value equals 0.0173). MOS-sleep scales measuring awakened short of breath or with headache, snoring, adequacy or drowsiness were not significantly different in the AIM group.

About AIM and ATTAIN

AIM was a Phase III multi-center, randomized, double-blind, placebo- controlled trial with 652 patients treated at baseline who had active RA despite MTX therapy (638 included in efficacy analyses). The study was double-blind through one year, followed by an ongoing, open-label, long-term extension study. A total of 376 (from the original 424) patients in the group treated with ORENCIA(R) (abatacept) entered the long-term extension study. Additional DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), and aspirin were added and/or adjusted at the discretion of the investigator in the long- term extension study. Primary reasons for discontinuation in the long-term extension studies were adverse events, withdrawal of consent, and lack of efficacy.

Primary endpoints were ACR 20 at six months ORENCIA vs. placebo (67.9 percent vs. 39.7 percent, respectively; p-value less than 0.001), clinically significant improvement in HAQ-DI at one year (63.7 percent vs. 39.3 percent, respectively; p-value less than 0.001), erosion score at one year (mean change from bas
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
(Date:12/17/2014)... Dec. 17, 2014  Northstar Global Business Services, ... Company (DTC) has made their final decision and ... the Company,s stock effective December 15, 2014, and ... for depository and book entry transfer services. All deposit ... now once again fully "DTC Eligible", and has ...
(Date:12/17/2014)... 17, 2014  IGI Laboratories, Inc. (NYSE MKT: IG; ... its offering of $125 million aggregate principal amount of ... Notes were offered and sold only to qualified institutional ... of 1933, as amended (the "Securities Act"). ... 3.75% per year, payable semiannually in arrears on June ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 2Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 3Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 4Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 5Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 6Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 7Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 8WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 2WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 3WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 4WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 5WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai 6
(Date:12/21/2014)... Mi (PRWEB) December 21, 2014 AlignLife ... child in need while at the same time helping people ... is a non-profit community-based organization committed to serving those persons ... meet their needs to improve the quality of life. Dr. ... make an impact in the local community and he knew ...
(Date:12/21/2014)... Portland, OR (PRWEB) December 21, 2014 ... discussing some of the issues and systemic barriers for ... ITU World Paratriathlon Champion. Scheidies has a condition called ... over time. He describes how he adapted his athletic ... to use his success in triathlon to pioneer the ...
(Date:12/21/2014)... 2014 The Oncology Institute of Hope and ... Ana and Whittier offices. The Hope for the Holidays Toy ... patients and their families during the holiday season. This year, ... 70 children between both offices. This event continues to be ... community service team, store managers and assistant managers came out ...
(Date:12/20/2014)... 2014 MissyDress, a distinguished special dress ... lovers. The business has drastically cut prices to all ... everyone until Jan. 30, 2015. Many of the hottest ... V-neck dresses, lace dresses, and more. , A spokesman ... every day. Whether A-line princess prom dresses or sweetheart ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
Breaking Medicine News(10 mins):Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... Experts from the University of Minnesota will soon be on ... emerging animal diseases that pose a threat to human health. ... team that will implement a United States Agency for International ... The project, called RESPOND, is one of five that ...
... defies belief that resistance wears thin much sooner , FRIDAY, ... provide immunity for an average of three decades, new research ... much less time. But the new study, by researchers based ... Mexico, rebuts that assumption. , Whooping cough, also ...
... ... , ... 2009 -- The U.S. President,s Emergency Plan for AIDS Relief (PEPFAR), the largest commitment ever ... founding partner. The partnership was announced by Ambassador Eric Goosby, U.S. Global AIDS Coordinator, who ...
... in circuits that regulate serotonin in certain parts of the ... cocaine-seeking, based on mouse studies published online this week in ... "The impetus for this research was our interest in ... in ways that lead to mood changes, depression, anxiety, and ...
... ... better our environment by offering green printing services and eco-friendly products to their customers, ... custom labels offering. , ... Fort Scott, KS (PRWEB) October 30, 2009 --, , , , ,My1Stop.com® expanded ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that net ... $0.43 per diluted share, versus $37.9 million, or $0.71 per diluted ... are in line with the preliminary earnings range that the Company ... elevated medical costs associated with the onset of what appears to ...
Cached Medicine News:Health News:U of M part of $185 million funded team tasked to improve global response to emerging pandemics 2Health News:U of M part of $185 million funded team tasked to improve global response to emerging pandemics 3Health News:Whooping Cough Immunity Lasts 30 Years or More 2Health News:U.S. President's Emergency Plan for AIDS Relief Joins mHealth Alliance 2Health News:U.S. President's Emergency Plan for AIDS Relief Joins mHealth Alliance 3Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 2Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 3Health News:My1Stop.com Launches New Custom Labels Solutions Making Pricing and Ordering Faster and Easier 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18
... is an expanded menu profiler designed to ... as 50 percent and deliver faster results ... AccuSense® glucose oxygen sensor, enhanced data management ... CX9 ALX system offers general and esoteric ...
... lab, the SYNCHRON LX4201 simplifies and speeds ... 2,880 tests per hour. By combining the ... with broad menu, speed and flexibility, your ... expect from Beckman Coulter-innovative, reliable systems that ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
... Workstation is the complete solution ... testing needs. , ,The workstation ... to expand with multiple applications ... reliability of working with the ...
Medicine Products: